ACST News and Press, Acasti Pharma Inc. From 01/13/20

Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP )  +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...

Acasti Pharma (NASDAQ: ACST )  -66%  after  unsuccessful results  from a Phase 3 TRILOGY 1 trial. More news on: Acasti Pharma Inc., Stage Stores, Inc., Five Below, Inc., Stocks on the move, Read more ...

Acasti Pharma (NASDAQ: ACST ) craters  60%  premarket on modest volume (thus far) in response to unsuccessful results from a Phase 3 clinical trial, TRILOGY 1 , evaluating lead candidate CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia. More news o...

Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks Despite pos...

Amarin ( AMRN ) has been re-defining the omega-3 market with last year's REDUCE-IT results, wherein they demonstrated that addition of Vascepa led to a 25% relative risk reduction in onset of first major cardiovascular event vs statin monotherapy. This was followed by a recent FDA label exp...

These 5 Penny Stocks Have Upcoming Milestones; How Will The Market React? This year was one to watch biotech penny stocks as a whole. We saw some of the most aggressive breakouts ever from many of these names. If you take a look at our article about penny stocks that crushed it in 2019 , yo...

Gainers:  China Rapid Finance (NYSE: XRF ) +142% . More news on: China Rapid Finance Limited, Liquidia Technologies, Inc., NewLink Genetics Corporation, Stocks on the move, Read more ...

B. Riley analyst Mayank Mamtani says Acasti Pharma's (NASDAQ: ACST )  24% pullback yesterday was "unwarranted" as the delay in CaPre drug data is likely "inconsequential" to the anticipated study results. More news on: Acasti Pharma Inc., Healthcare stocks news, Stocks on the mo...

Expects to report Trilogy 1 topline results in January 2020 with topline results for Trilogy 2 still expected by the end of January 2020 LAVAL, Québec, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX...

Can These Stocks Continue Higher Before Friday? Over the course of the year so far, plenty of penny stocks have generated highly impressive gains for investors. As the year comes to a close, there are still some penny stocks to watch that also show impressive momentum. When it comes to th...